share momentum upgrad buy
overhang growth momentum multipl sourc
understand investor concern growth slow tough comp
see sever sourc growth allow deliv upsid con
upgrad share buy neutral chang
pt see upsid favor risk reward skew deriv
less revenu anima patient next year think gap fill
sever sourc pump market growth acceler take share
take high share new patient attract product offer ou
under-penetrated launch basal iq year control iq
next year control iq expect launch us late
expect big impact growth renew increas launch
next-gen sport call provid color longer
term target includ new instal base goal see print control iq
launch updat posit catalyst
share under-perform even busi improv
share under-perform mo good start year share
broken past month competitor share
increas trade ev/sal vs high ntm sale
contrast trade sale near all-tim high
publish data ub evid lab diabet physician survey think
support thesi diabet patient volum pump penetr
grow impli robust pump market growth next two year
expect gain share share gain expect improv markedli
year ago slim score well pump technolog
posit mention eas use connect cgm upgrad
valuat pt base sale mm
trade rev well peak price target
assum multipl expand given driven least mid growth next year
upsid consensu estim
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price oct edt
report prepar ub secur llc except core rate band page analyst certif
requir disclosur begin page ub seek busi compani cover research
report result investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
ub research thesi map guid think report
 market grow
analysi ub evid lab diabet survey show expect annual growth
pump volum next yr vs project low-mid teen view posit
pump compani includ pump market growth appear acceler
 tandem grow pump market rate
seem like signific product momentum latest ub evid lab survey
net posit score share gain notabl increas markedli
survey year ago attribut launch slim basal iq
 artifici pancrea game changer
ye physician survey excit artifici pancrea system call game
chang view posit given basal iq launch control iq
system shown improv clinic outcom high patient satisfact
buy rate base view seen strong revenu growth recent
iter pump devic analysi ub evid lab survey result posit
prospect grow given market growth expect share gain opportun close loop
system stock under-perform think give investor attract opportun
ub evid lab diabet survey suggest pump market growth well histor
rate second term share gain expect score improv markedli
year ago reflect posit real world perform basal iq system control iq trial
view physician survey call artifici pancrea game chang bode well
uptak system us ou view
share weak valuat sale vs peak ntm sale last
year stock regain momentum back strong result expect next year
focus design develop commerci product peopl
insulin-depend diabet flagship product slim insulin
mo sale impliedsourc ub downsidesourc driversavg growth ebit epspump market growth ub research
 market grow
analysi ub evid lab diabet survey show expect
annual growth pump volum next yr vs project
low-mid teen view posit pump compani includ
pump market growth appear acceler
notabl data ub evid lab diabet physician survey impli
pump market growth next two year think
like bit inflat good sign see pump market growth
acceler forecast low-mid teen market growth next three
consensu model pump market growth low doubl digit given
advent new technolog appear market acceler
call doubl mdi convers patient versu
market growth acceler given new technolog includ
slim improv eas use clinic perform
seen patient adopt pump think launch close loop system
partial respons surg notabl data ub evid
lab diabet physician survey impli pump market growth next
two year think like bit inflat good sign see
pump market growth acceler forecast low-mid teen market growth
next three year
figur patient penetr increas impli compound-annual-growth-rate
specif talk histor market new
pumper come market year pump shipment
us come multipl daili inject mdi patient
base strength channel comment think
number mdi patient come market could doubl
past peopl given take high share new patient
well posit opportun
next year think pump penetr shift
data ub evid lab diabet physician survey would support
notion show wave survey physician expect pump
penetr increas today year
increas two year magnitud increas patient
even larger term increas
figur insulin use could increas
yr yr peak penetr insulin yr yr peak penetr insulin pump ub research
 tandem grow pump market rate
seem like signific product momentum latest ub
evid lab survey net posit score share gain
notabl increas markedli survey year ago
attribut launch slim basal iq
take share take high share new patient attract
product offer think benefit issu
initi launch heard physician
interview hurt pump reput time
slim score well new product standpoint given
eas use upgrad combin cgm latest ub
evid lab survey net posit score share gain
notabl increas markedli survey year ago
attribut launch slim basal iq side note
score still posit year
consensu model growth market think
could grow low-mid teen geographi includ growth us
growth intern market given factor
discuss think could drive upsid consensu next year
model upsid consensu estim conserv
take share take high share new patient
attract product offer think benefit
issu initi launch heard physician
interview hurt pump reput time
slim score well new product standpoint given eas
use upgrad combin cgm latest ub evid lab
survey net posit score share gain notabl
increas markedli survey year ago attribut
launch slim basal iq side note score
still posit year ago notabl us patient
come market year return pump purchas
figur physician vote compani gain share vote
recogn opportun pursu modest expans us
sale forc expect territori year end
highlight independ market research show custom
satisfi work today highlight continu work
develop best pump market count possibl
tubeless dispos pump futur know coverag
could happen optimist unit could provid coverag
futur given control iq peer-review data said
think unit coverag would huge pop busi
revenu prior non-coverag
medicalbeta bionicsoth respond gain
 ou under-penetrated penetr launch
basal iq year control iq next year europ
launch product next year market structur rel similar
us region differ reimburs coverag
expect market growth share dynam rel similar us
give us confid gain share eu basal
control highlight score well overal technolog high
rank accuraci eas use clinic benefit
figur guardian led best overal technolog
shift distributor focu regular market activ
much anima convers opportun pass today
market cover pumper expect geographi cover
pumper total next year near term focus
largest european market begin roll countri
next month germani area final
convers get distribut partner place note sizeabl
mani countri low penetr vs
patient us think technolog like basal iq launch
drive higher give strong share gain opportun outsid us
comment surpris level demand
countri patient organ look new pump
road ou look expand asia place point
may look convert attract market direct unlik
done view
renew increas given year reimburs cycl begin
see increas renew pump sale occur year ago given
growth averag high double-digit past year
tailwind continu build estim
in-warranti instal base patient base cumul number
pump ship past four year us pump shipment includ
doubl renew includ sale warranti expir far back
orolderinsuletomnipodtandemt slimbeta bionicsbigfootmedicalwav rank pump best overalltechnolog
pleas progress regard custom retent
renew work deliv good four year patient experi
end period get renew
build instal base also see strong growth suppli
grew y/i last quarter next year suppli piec continu
grow strongli given pace pump addit saw
expect come year
time note anima repres
pump shipment despit see doubl volum come versu past
look forward expect cliff anima patient stop
think tail anima patient continu come next
year help buffer downsid
launch next-gen sport sport essenti
size omnipod still tube pump think form factor
improv make pump attract use valu discret
also note featur like detach make sport conveni use
highlight market research support idea mdi
pediatr patient would interest sport make posit stronger
key popul sport also mobil control patient use
phone control pump ad discret use pump
 artifici pancrea game changer
ye physician survey excit artifici pancrea system
call game chang view posit given basal
iq launch control iq system shown
improv clinic outcom high patient satisfact
data ub evid lab diabet physician survey support notion
uptak close loop system increas nearli half physician
survey view close loop system game chang physician think
mani intens patient use
popul anoth say use
system notabl expect gather data control iq
go back payer organ
look addit
think consensu under-appreci import control iq
studi time rang view disappoint initi
versu expect view differ
mid clinic relev achiev difficult all-
comer real world popul includ new pumper cgm user
make outcom impress
control iq launch us late expect big
impact growth importantli control iq back data landmark
nih run studi took comer deliv impress result term time
rang studi design broad inclus criteria folk low
high one never use cgm pump make
repres real world see data present ada june
clinician room call studi new standard trial run
time patient studi overwhelmingli want continu use
devic rate experi highli month qol metric
posit greater scale
us launch initi patient also run studi
lower age notabl estim custom
basal iq enabl pump today updat
pump stage base cgm view
bode well futur control iq adopt repres increment
opportun patient continu adopt cgm said
partnership non-exclus would like consid relationship
cgm product icgm design materi market share
integr anoth straightforward sensor
could take least month libr process would longer
would need understand data commun come libr
figur
data ub evid lab diabet physician survey support notion
uptak close loop system increas nearli half physician survey
view close loop system game chang physician think mani
intens patient use popul
anoth say use system notabl
expect gather data control iq go back payer
organ look addit reimburs
figur view close loop hybrid close loop system
around physician expect mani intens manag patient
use artifici pancrea
figur percentag patient expect manag artifici
ub evid lab question mani patient expect use system
valuat attract driven improv busi growth
momentum back ub evid lab data
look high-growth med-tech name see rang valuat typic
sale name profit base structur compani
end market tam profit potenti scarciti valu growth durabl
factor
show chart highlight differ name grow
mid rang wide rang valuat depend differ
factor note one higher valuat group
closer middl pack despit higher growth
especi growth year given anima benefit launch basal
figur small mid-cap med-tech valuat averag growth vs ev/sal
diabet name premium trade meaning discount
diabet name like garner premium valuat
due exposur attract end market larg see
signific growth rise tide due advanc technolog
drive true clinic benefit diabet popul larg ww
therapi remain under-penetrated despit clear patient benefit
penetr estim popul us
ww european countri rang
technolog improv increasingli use connect system think
penetr rise suggest survey data lead long growth
addit pump compani becom increasingli profit due
greater scale chang made autom manufactur
talk pathway higher gross margin
target gm see sever hundr basi point
margin opportun product becom better easier use also
think cost serv patient go think less custom servic
lead oper margin benefit could lead om
rang longer term help us tie sales-bas target real futur cash flow
think deserv premium given made
progress profit higher gm dispos
durabl pump give access pharmaci channel potenti make
easier acquir allow pay go use could import
market pump use could intermitt use temporarili make
theoret larger despit see premium wide
think share close gap strong perform next
quarter
trade turn closest comp also trade turn
anoth fast grow diabet pure play note tndm year
valuat rang podd rang averag
trade rev well max
rang price target sale mm
diabet median multipl assum current multipl expand expect
consist least revenu growth next year upsid
consensu estim current premium versu three
year averag
slight chang estim account higher renew
ou confid
bump estim account higher renew
assumpt increas confid ou growth think tail
anima patient europ entri larg new market could
allow grow ou next year vs prior assumpt growth would
modest
wrong think key area could thwart
thesi stage take signific share
competit convers repres half non-renew pump revenu
us mostli expect launch system
improv sensor next month success significantli
improv perform could thwart share gain second pump
market growth pick unclear sustain could think
technolog momentum keep growth group high possibl
could temporari
ev/salesabsolut avgev/sal rel average rel ev/salesabsolut avgev/sal rel average rel ub research
upsid upsid case assum achiev sale growth
also factor ebit margin pump market
growth
base base case assum achiev sale growth
also factor ebit margin pump market
growth mid-teen
downsid downsid case assum achiev sale
growth also factor ebit margin pump
market growth
mo sale impliedsourc ub downsidesourc driversavg growth ebit epspump market growth ub research
revenu region
tandem diabet focus design develop
commerci product peopl insulin-
depend diabet flagship product slim
insulin deliveri system slim base tandem
proprietari technolog platform tandem headquart
san diego california
particip diabet market provid insulin
peopl us diagnos
diabet diabet classifi type
type us type
patient type patient requir insulin
type insulin intens type patient need daili
rapid-act insulin manag diseas also
need frequent glucos monitor via either cgm finger
stick part insulin treatment global cgm
market estim grow
ub evid lab sell-sid team expert independ ub research work
across practic area special lab creat insight-readi dataset expert turn
data evid appli combin tool techniqu harvest cleans
connect billion data item month sinc ub research analyst util
expertis ub evid lab insight-readi dataset compani sector theme
result product differenti ub research report ub evid lab
provid research invest recommend advic provid insight-readi
dataset analysi ub research client
report leverag ub evid lab endo pcp diabet cgm insulin survey
asset ub evid lab conduct on-line interview among us physician
specialti endocrinolog primari care intern medicin usual multipl year
experi treat patient type insulin intens type diabet
interview conduct juli august
wave conduct august septemb
wave conduct decemb februari read
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
valuat method risk statement
price target base revenu estim
mm risk price target includ slowdown insulin pump
other price
reimburs risk regulatori risk around pipelin lack insur
coverag margin pressur cost inflat busi execut
problem intern distribut
price target base revenu mm
risk price target includ slowdown insulin pump market
competit other price reimburs risk
regulatori risk around pipelin lack insur coverag margin
pressur cost inflat busi execut
